Oct 08, 2019 / 03:30PM GMT
Gbolahan Amusa - Chardan Capital Markets, LLC, Research Division - Director of Research & Head of Healthcare Research
Thanks, everyone, for joining. We'll start our next fireside chat with Dr. Stephen Hoge, President of Moderna Therapeutics. Stephen, thanks for joining us and thanks for partaking in our earlier panel, the next big thing in genetic medicines.
Stephen Hoge - Moderna, Inc. - President
Thanks for having me.
Gbolahan Amusa - Chardan Capital Markets, LLC, Research Division - Director of Research & Head of Healthcare Research
So please start with just introductory comments on Moderna including recent highlights and any upcoming catalysts you'd like to emphasize.
Stephen Hoge - Moderna, Inc. - President
Sure. So briefly, Moderna, for those who don't know, we're a little bit different than a lot of the other technologies that are out here. We're focused entirely on messenger RNA as a company, non-DNA-based approaches. And we have a diversity of programs.
Moderna Inc at Chardan Genetic Medicines Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot